#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts RESSET RCT +RA #RCT w #VNS But low response with stat significance ACR20 1/4 sham vs 1/3 VNS Would add on to new SoC? 🤔 #EULAR2025 @RheumNow #eular_org #D2T- RA-session https://t.co/tR1pLPBr74

• https://x.com/Janetbirdope/status/1933175424118296913/photo/1
• https://x.com/Janetbirdope/status/1933175424118296913/photo/1

cool stuff at #EULAR2025 RESET #RCT - #vagal #nerve #stimulation #VNS vs sham in #RA w 1or >1 #bDMARD-IR N=242 D/C bDMARD, on #csDMARD #RA 12 yrs, 10SJC 12TJC 2.6 b/tsDMARD failure Wk12 EULAR good/mod response 61v 42% Sham▶️goes VNS ✅data= @RheumNow @eular_org abst#OP190

#RITAZAREM: infection risk during RTX induction in AAV was ↑ w/ lung disease & nodules/cavities; ↓ w/ TMP-SMX prophylaxis. Early infections predicted later ones, but risk didn’t differ by RTX vs AZA. Pulmonary damage is a key red flag for infection @RheumNow #EULAR2025 #OP0167

#infections in #JAKi @drdavidliew #JAKi sl ⬆️ infection risk vs #TNFi ⬆️HZ w JAKi JAKi same risk w #latent #TB #LTBI and new TB ⬇️in JAKi v bDMARDs He didn’t discuss TYK2i Reassuring - risk⬇️ over time for infection @RheumNow #EULAR2025 @eular_org JAKi & infection https://t.co/KVsY2gXVkQ

• https://x.com/Janetbirdope/status/1933139579294621997/photo/1
• https://x.com/Janetbirdope/status/1933139579294621997/photo/1

JAKi: expanding RMD indications—but important safety concerns to consider ⚠️ Cancer: Neutral vs MTX/placebo, ↑ risk vs TNF ⚠️ Infection: ↑ with age, disease activity & GC use—not uniformly higher with JAKi 🗣️ Patients rank infection risk as top concern @rheumnow #EULAR2025 https://t.co/RJRDWQjqNC

• https://x.com/JihaRheum/status/1933140654827434066/photo/1
• https://x.com/JihaRheum/status/1933140654827434066/photo/1

Age & dose ⬆️ infections in JAKi Not all JAKi are created w equal risk ⁦@RheumNow⁩ ⁦@eular_org⁩ #EULAR2015 ⁦@drdavidliew⁩ #JAKi & #infection https://t.co/F7zLUBuzJR

• https://x.com/Janetbirdope/status/1933140984277156104/photo/1

Rheumatology #AI to optimize rheumatology triage. Only 53 percent correlation between the AIs diagnosis with rheumatologists final diagnosis. Not sure if we want 47 percent pts to drop off...without a chance for diagnosis? #POS0883 #EULAR2025 @RheumNow https://t.co/UWsCHG00t1

• https://x.com/bella_mehta/status/1933156408989532478/photo/1

#D2T #RA ~20% #Polyrefractory 3% Many reasons for d/c ing #Rx - D2T AEs Intolerance Chronic pain Etc My approach is different depending on reasons why drugs were d/c Ie ?obj inflammation vs pain or intolerance @RheumNow @eular_org #EULAR2025 #whatmakes D2T RA difficult https://t.co/AL6TMVJIk9

• https://x.com/Janetbirdope/status/1933161013836226975/photo/1

POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts. Tofa & bari took biggest hits; upa growth slowed but offset losses. Real-world prescribing adapts—but doesn’t abandon. @RheumNow #EULAR2025 https://t.co/QZ5haW2vhX

• https://x.com/JihaRheum/status/1933147276005822711/photo/1

Fascinating to see JAKi uptake in European JAK-pot centres - tofa was already on the decline pre-ORAL Surveillance - JAKi use (driven by upadacitinib) continues to grow, although maybe it’s slowed Hopefully rational JAKi has its place #EULAR2025 POS0150 @RheumNow https://t.co/XRyHJVw821

• https://x.com/drdavidliew/status/1933155241043910719/photo/1

In #SLE, #HCQ levels >1150 ng/ml ↑toxicity risk w/o added benefit. Levels 750-1150 ng/ml linked to ↓disease activity. CKD stage ≥3 doubled HCQ levels at same dose. Supports monitoring & dose adjustment in CKD to balance safety & efficacy. @RheumNow #EULAR2025 #OP0199

PHOENYCS GO🏃: Dapirolizumab pegol (DZP) led to higher rates of LLDAS (41% vs 20%) & DORIS remission (19% vs 8%) at wk48 vs PBO+SOC. DZP showed earlier & more sustained disease control, advancing T2T in SLE. @RheumNow #EULAR2025 #OP0201 https://t.co/zuxBELxTDd

• https://x.com/DrMiniDey/status/1933088383548420596/photo/1

Ph 2 RCT CPL'116 dual inhibition JAK/ROCK 106 MTX IR pts wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO 75% >= AEs, SAE 2: 1 MI, 1 bladder cancer Authors suggest absence of lipids/LFTs disruption compared to other JAKs Ph3 is awaited!! #OP0193 #EULAR2025 https://t.co/TnnM410LfM

• https://x.com/AurelieRheumo/status/1933090354623905889/photo/1
• https://x.com/AurelieRheumo/status/1933090354623905889/photo/1
• https://x.com/AurelieRheumo/status/1933090354623905889/photo/1
• https://x.com/AurelieRheumo/status/1933090354623905889/photo/1

OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all? In >1,100 RA pts, no link to liver fibrosis (FIB-4/APRI), modest ALT ↑, and fewer hospitalizations. real-world safety data worth a second look. @RheumNow #EULAR2025

ACQUIVAS: RTX-treated AAV patients had poor response to #pneumococcal vaccine PCV-13 (8% vs 45% in non-RTX). Boosting w/ PPV-23 helped a few but 48% failed to mount robust response. Time to rethink vaccine strategies in RTX-treated patients? @RheumNow #EULAR2025 #OP0173 https://t.co/soU5qfwRib

• https://x.com/DrMiniDey/status/1933097191532585263/photo/1